Spero Therapeutics (SPRO) Income towards Parent Company (2016 - 2026)

Spero Therapeutics (SPRO) has 11 years of Income towards Parent Company data on file, last reported at -$7.2 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company rose 48.06% year-over-year to -$7.2 million; the trailing twelve-month figure through Mar 2026 stood at $15.2 million (up 120.72% YoY), and the FY2025 full-year result was $8.6 million, up 112.48% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$7.2 million, down from $31.5 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $55.1 million in Q4 2023 and bottomed at -$30.1 million in Q1 2022.
• The 5-year median for Income towards Parent Company is -$11.9 million (2023), against an average of -$5.0 million.
• The widest annual swing landed in 2024, when Income towards Parent Company sank 454.02%; it then soared 230.92% in 2025.
• A 5-year view of Income towards Parent Company shows it stood at $27.5 million in 2022, then soared by 100.51% to $55.1 million in 2023, then tumbled by 143.68% to -$24.1 million in 2024, then jumped by 230.92% to $31.5 million in 2025, then slumped by 122.85% to -$7.2 million in 2026.
• The last three Income towards Parent Company figures came in at -$7.2 million (Q1 2026), $31.5 million (Q4 2025), and -$7.4 million (Q3 2025), per Business Quant data.

Peer Comparison